Explore hgh fragment 176-191 calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.
Anonymized hgh fragment 176-191 calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.
HGH Fragment 176-191 is the fat-mobilizing C-terminal fragment of human growth hormone, most often sourced for lipolysis and body-composition research. It ships as a lyophilized powder you reconstitute with bacteriostatic water, and is closely related to — but not identical to — the tyrosine-extended analog AOD-9604, which is the version that actually reached human trials.[1]
Native growth hormone exerts its lipolytic effect through a distinct C-terminal domain that does not require IGF-1 or the classical JAK2/STAT5 cascade triggered by GH-receptor activation. HGH Fragment 176-191 retains this lipolytic activity in adipocyte assays while losing the anabolic, insulin-antagonist, and hyperglycemic effects of the full-length hormone — at least in animal models.[2]
Pre-clinical work demonstrated reduced adipose mass, increased fat oxidation, and absence of hyperglycemia in obese rodent models.[2] The tyrosine-extended analog (AOD-9604) reached a 12-week Phase 2b trial in obese adults (Heffernan / Ng programs), reporting modest weight loss vs. placebo before the program was halted.[3] The non-tyrosylated 176-191 fragment itself has not been the subject of a published controlled human trial.
Not FDA-approved. Clinical development discontinued in 2007. Sold as a research peptide only.
HGH Fragment 176-191 has a reported half-life of ~30 min. The pharmacokinetic reference models an interval of once or twice daily (fasted); this is not a measured community cadence or a dosing recommendation. Very short half-life — each dose is gone within a few hours with no buildup between days, so timing relative to fasting matters more than steady-state level. Pharmacokinetic source: Pre-clinical pharmacokinetic estimates; not characterised in humans. It is catalogued under Weight Loss on WPA.
233 HGH Fragment 176-191 reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
WPA Analysis
HGH Fragment 176-191 is the unstabilized parent of AOD-9604, and the two molecules are best understood together. The C-terminal 16 amino acids of human growth hormone were characterized in the 1990s as the region of the molecule that retains hGH's lipolytic and anti-lipogenic activity while leaving behind the IGF-1-driven somatogenic effects that make full-length hGH a growth-promoting hormone — the work running through Wu et al. and Ng et al. on hGH 177-191's effect on adipocyte lipolysis. Metabolic Pharmaceuticals later took that fragment, added a tyrosine to the N-terminus to improve stability and shelf life, and developed it as AOD-9604 — which advanced into multiple Phase II obesity trials in the mid-2000s and ultimately failed to demonstrate weight-loss efficacy versus placebo at oral doses up to 30mg/day. The unstabilized 176-191 fragment that researchers buy directly today was never advanced through a Phase II human program, holds no approved indication anywhere in the world, and has no published controlled clinical evidence at the small-mcg subcutaneous dose range modern researchers actually use.
Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.
WPA DOSING INSIGHT
The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.
WPA RECONSTITUTION INSIGHT
Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.